FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/080130 [Registered on: 07/02/2025] Trial Registered Prospectively
Last Modified On: 04/02/2025
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Case Control Study 
Study Design  Other 
Public Title of Study   Study to identify clinically actionable genes and multi-omics based tear biomarkers in early-onset keratoconus 
Scientific Title of Study   A comprehensive multi-omics based approach to identify clinically actionable genes and tear fluid-based biomarkers in early-onset keratoconus 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ramkishor Sah 
Designation  Scientist 
Affiliation  Dr. R P Centre, All India Institute of Medical Sciences (AIIMS) 
Address  Room No-104, First Floor, Cornea and Contact Lens Services, Dr. R P Centre, AIIMS, Ansari Nagar, New Delhi

New Delhi
DELHI
110029
India 
Phone  9999777632  
Fax  26588919  
Email  ramkishorsah@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ramkishor Sah 
Designation  Scientist 
Affiliation  Dr. R P Centre, All India Institute of Medical Sciences (AIIMS) 
Address  Room No-104, First Floor, Cornea and Contact Lens Services, Dr. R P Centre, AIIMS, Ansari Nagar, New Delhi

New Delhi
DELHI
110029
India 
Phone  9999777632  
Fax  26588919  
Email  ramkishorsah@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ramkishor Sah 
Designation  Scientist 
Affiliation  Dr. R P Centre, All India Institute of Medical Sciences (AIIMS) 
Address  Room No-104, First Floor, Cornea and Contact Lens Services, Dr. R P Centre, AIIMS, Ansari Nagar, New Delhi

New Delhi
DELHI
110029
India 
Phone  9999777632  
Fax  26588919  
Email  ramkishorsah@yahoo.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Indian Council of Medical Research 
Address  Department of Health Research, Ministry of Health and Family Welfare, V.Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi - 110029, India 
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ramkishor Sah  Dr. R P Centre, AIIMS, New Delhi  Room No-104, First Floor, Cornea and Contact Lens Services, Dr. R P Centre, AIIMS, Ansari Nagar, New Delhi
New Delhi
DELHI 
9999777632
26588919
ramkishorsah@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute Ethics Committee, AIIMS, Ansari Nagar, New Delhi  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: H186||Keratoconus,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  NIL  NIL 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  a Either Sex
b Age ≥ 18 Yrs.
c Sporadic (non-inherited) cases of KC (with or without their family member)
d No corneal scarring
e Patient willing to give consent for the study
 
 
ExclusionCriteria 
Details  a Patients under the age of 18 Yrs.
b Cases of KC with previous corneal transplantation/post-LASIK Ectasia etc.
c History of previous ocular disease, surgery, or trauma
d Patient not willing to participate in the study
e Patients not willing for investigations, tear fluids and blood sampling
f Corneal scarring, ocular diseases such as glaucoma, uveitis, or ocular infections
g History of systemic diseases such as diabetes, autoimmune disorders or cancer
h Patients who are pregnant or breastfeeding
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
In this current study, we plan to undertake a multi-omics based integrative approach to achieve the following objectives:

Comprehensive integrated sequencing, tear proteomics, candidate gene validation and de novo approach to identify altered targets, biomarkers, and clinically actionable novel variants in keratoconus
 
3-Years 
 
Secondary Outcome  
Outcome  TimePoints 
NA  0.00 
 
Target Sample Size   Total Sample Size="80"
Sample Size from India="80" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   03/03/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

      Keratoconus (KC) is an eye disease that affects the thinning and irregularities of the corneal surface, developing in loss of vision. It occurs in approximately 1 in 2,000 individuals, typically beginning in puberty and progressing into early adulthood. Keratoconus is a complex and multifactorial disease resulting from the interplay of genetics and the environment. The exact role of genetics in keratoconus remains to be understood. The whole exome sequencing of the all protein-coding portion of the human genome by Next-generation sequencing (NGS) is a powerful and cost-effective method for the detection of disease variants underlying complex disease pathogenesis that is unprecedented in the field of keratoconus. This study particularly focuses on the genetic view of KC with both common polymorphisms as well as rare functional exonic variations. Since hypothesis-based approaches such as single candidate gene or targeted gene sequencing will only explore the selected genes. If the genetic factors underlying the disease are not situated in those genes, they cannot be picked up. This present study is the earliest effort to address early keratoconus patients through a hypothesis-free approach; whole-exome sequencing of all protein-coding regions of the genome. We propose a gene-centric approach for Indian patients with keratoconus. Understanding the genetics of KC likely provides some DNA-based diagnostic tool or novel therapeutic targets for disease prevention, early diagnosis to manage these cases before irreversible damage to the cornea, and management of the KC by delaying or arresting its progression; and improving the treatment of this severe vision-threatening eye problem.
   

    Keratoconus is a non-inflammatory, bilateral asymmetric and multifactorial ectatic disease of the cornea with a large impact on global health. It is characterized by stromal thinning, steepening and protrusion of the cornea that results in a conical shape leading to irregular astigmatism. The gradual stromal thinning, rupture of the anterior limiting membrane (basal membrane of the corneal epithelium), remodeling of the extracellular matrix and subsequent ectasia of the central & paracentral cornea are the most observed clinical & histopathological findings. These abnormal corneal configurations induce optical irregularity, contrast sensitivity, high order aberrations, decrease of visual acuity which leads to progressive myopia and astigmatism becoming more irregular. A family history of keratoconus, environmental stimuli, insults, oxidative stress, genetic predisposition, and allergy are risk factors for developing keratoconus. There are multiple associations of conventional risk factors such as frequent eye rubbing, presence of atopic diseases, exposure to UV light, comorbidities have been reported. Usually, the condition has been described as a noninflammatory disease; however, some recent studies reported it has been associated with ocular inflammation. KC is usually beginning in puberty age and manifested in the second or early third decades of early adulthood with equal distribution in males and females. The latest available estimate is 1in 2000 in the general population. The conventional and traditional conservative management of keratoconus begins with spectacle correction and contact lenses in early stages. With progression of the disease into more advanced and severe cases with corneal scarring may be needed corneal transplantation to restore useful vision to the eye. KC has been emerged as one of the leading eye health problems and rapidly increasing amongst Indians. Its burden has been to be estimated at nearly 2.3% in Indians (aged 30 years and above) in the rural region of Central India, but the exact prevalence is not known.


    Keratoconus is a progressive and complex disorder caused by both genetic and environmental factors. It’s a shared complex interplay between genetics and environment that is accompanied by corneal ectasia and progresses asymmetrically. The heredity of keratoconus has not yet been clearly established. The genetic architecture of KC is complex. So far various linkage, Genome-Wide-Association Study and candidate gene studies have identified a few genetic variations which show variable nature of their reproducibility among KC population across different geographical regions. The implicated common variations have been hypothesized to play a role on KC pathology with small effects and/or through genetic interaction between multiple genes. All the implicated strategies are mainly based on hypotheses or a single study and these are not replicated in a different region. Therefore, there is an extensive need to analyze the whole exome/genome to find out the causative genetic factor. Whole exome sequencing (a hypothesis-free approach) of all coding genes will help us to identify the potential role of rare functional variants in new susceptibility genes of KC disorder. The genetic component of KC in the Indian population is poorly understood therefore it is essential to characterize genetic risk factors in the Indian population.

 
Close